PDF herunterladen
Semin Thromb Hemost 2013; 39(01): 112
DOI: 10.1055/s-0032-1333535
Erratum
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Effect of Genetic Variants, Especially CYP2C9 and VKORC1, on the Pharmacology of Warfarin

Autoren

  • Erik Fung

    1   Section of Cardiology, Heart & Vascular Center, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire
    2   Geisel School of Medicine at Dartmouth, Dartmouth College, Hanover, New Hampshire

  • Nikolaos A. Patsopoulos

    3   Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
    4   Division of Genetics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
    5   Broad Institute of Harvard and MIT, Cambridge, Massachusetts

  • Steven M. Belknap

    6   Department of Medicine, Northwestern Feinberg School of Medicine, Northwestern Memorial Hospital, Chicago, Illinois

  • Daniel J. O'Rourke

    1   Section of Cardiology, Heart & Vascular Center, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire
    2   Geisel School of Medicine at Dartmouth, Dartmouth College, Hanover, New Hampshire
    7   Section of Cardiology, Veterans Affairs Medical Center, White River Junction, Vermont

  • John F. Robb

    1   Section of Cardiology, Heart & Vascular Center, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire
    2   Geisel School of Medicine at Dartmouth, Dartmouth College, Hanover, New Hampshire

  • Jeffrey L. Anderson

    8   Cardiovascular Department, Intermountain Medical Center, Murray, Utah
    9   University of Utah School of Medicine, Salt Lake City, Utah

  • Nicholas W. Shworak

    1   Section of Cardiology, Heart & Vascular Center, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire
    2   Geisel School of Medicine at Dartmouth, Dartmouth College, Hanover, New Hampshire
    10   Department of Pharmacology and Toxicology, Geisel School of Medicine at Dartmouth, Dartmouth College, Hanover, New Hampshire

  • Jason H. Moore

    2   Geisel School of Medicine at Dartmouth, Dartmouth College, Hanover, New Hampshire
    11   Institute of Quantitative Biomedical Science, Dartmouth College, Hanover, New Hampshire
    12   Departments of Genetics and Community and Family Medicine, Geisel School of Medicine at Dartmouth, Dartmouth College, Hanover, New Hampshire
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
31. Dezember 2012 (online)

  Lizenzen und Reprints

Originalartikel zu diesem Erratum:

Effect of Genetic Variants, Especially CYP2C9 and VKORC1, on the Pharmacology of WarfarinSemin Thromb Hemost 2013; 39(01): 893-904
DOI: 10.1055/s-0032-1328891

The publisher regrets an error in a sentence in the above article in Seminars in Thrombosis & Hemostasis, Volume 38, Number 8, p. 900. The correct sentence is as below:

In the latest prospective, clinical effectiveness trial, pharmacogenetic guidance was found to decrease the OOR INR by 12%.17